Technology area: Biotechnology & Pharmaceuticals
8 pending office actions • 6 art units • 8 examiners • 0 of 8 (0%) have an AI response strategy ready • 14 patents granted in the last 365 days
Deciphera Pharmaceuticals LLC is currently navigating 8 pending office actions in the Biotechnology & Pharmaceuticals sector. These 8 actions are distributed among 8 distinct examiners, ensuring that no single examiner manages more than one case. The portfolio spans 5 distinct art units, which indicates that the subject matter is being reviewed across several specialized groups within the office. John D Pak is the busiest examiner with 1 pending action.
The use of 5 art units suggests that the company's research is being classified into multiple technical categories. This ratio of actions to examiners implies a diverse range of perspectives during the examination process. Practitioners should be prepared to address the specific nuances of 8 different examiners while maintaining a unified prosecution strategy. The distribution of the portfolio ensures that the outcome of any single case does not disproportionately affect the overall pending workload. Each of the examiners will bring a unique interpretation to the biotechnology and pharmaceutical innovations under review.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (25%) |
| Double-patenting only | 1 (12%) |
| Double-patenting + other | 1 (12%) |
| Multi-statute (no §101) | 4 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PAK, JOHN D | 1 | 52.3% | +37.8% |
| LEE, SIN J | 1 | 68.8% | +25.1% |
| NESTOR, DONNA MICHELLE | 1 | 56.6% | +44.2% |
| SEITZ, ANTHONY JOSEPH | 1 | 67.8% | +27.5% |
| KIFLE, BRUCK | 1 | 79.3% | +15.8% |
| SZNAIDMAN, MARCOS L | 1 | 37.4% | +16.1% |
| VALENROD, YEVGENY | 1 | 72.5% | +25.1% |
| RODRIGUEZ, RAYNA B | 1 | 33.6% | +19.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17845275 | USE OF 1-[4-BROMO-5-[1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL]-2-FLUOROPHENYL]-3-PHENYLUREA AND ANALOGS FOR THE TREATMENT OF CANCERS ASSOCIATED WITH GENETIC ABNORMALITIES IN PLATELET DERIVED GROWTH FACTOR RECEPTOR ALPHA | RODRIGUEZ, RAYNA B | 12d |
| 19544595 | FORMULATIONS OF VIMSELTINIB | LEE, SIN J | — |
| 18980378 | VPS34 INHIBITORS AND METHODS OF USE THEREOF | NESTOR, DONNA MICHELLE | — |
| 18971800 | SOLID FORMS OF AN ULK INHIBITOR | SEITZ, ANTHONY JOSEPH | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18464519 | METHODS OF TREATING GASTROINTESTINAL STROMAL TUMORS | VALENROD, YEVGENY | 24d overdue |
| 17845275 | USE OF 1-[4-BROMO-5-[1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL]-2-FLUOROPHENYL]-3-PHENYLUREA AND ANALOGS FOR THE TREATMENT OF CANCERS ASSOCIATED WITH GENETIC ABNORMALITIES IN PLATELET DERIVED GROWTH FACTOR RECEPTOR ALPHA | RODRIGUEZ, RAYNA B | 12d |
| 19545401 | FORMULATIONS OF VIMSELTINIB | PAK, JOHN D | — |
| 19544595 | FORMULATIONS OF VIMSELTINIB | LEE, SIN J | — |
| 18980378 | VPS34 INHIBITORS AND METHODS OF USE THEREOF | NESTOR, DONNA MICHELLE | — |
| 18971800 | SOLID FORMS OF AN ULK INHIBITOR | SEITZ, ANTHONY JOSEPH | — |
| 18770318 | PHENYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | KIFLE, BRUCK | — |
| 18389888 | METHODS OF TREATING GASTROINTESTINAL STROMAL TUMORS | SZNAIDMAN, MARCOS L | — |
| Art Unit | Apps |
|---|---|
| 1628 | 3 |
| 1699 | 1 |
| 1613 | 1 |
| 1627 | 1 |
| 1629 | 1 |
| 1624 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19545401 | FORMULATIONS OF VIMSELTINIB | PAK, JOHN D | 1699 | §103§112DP | Final Rejection | — | Pending | Feb 20, 2026 |
| 19544595 | FORMULATIONS OF VIMSELTINIB | LEE, SIN J | 1613 | §102§103§112 | Final Rejection | — | Pending | Feb 19, 2026 |
| 18980378 | VPS34 INHIBITORS AND METHODS OF USE THEREOF | NESTOR, DONNA MICHELLE | 1627 | §103§112 | Non-Final OA | — | Pending | Dec 13, 2024 |
| 18971800 | SOLID FORMS OF AN ULK INHIBITOR | SEITZ, ANTHONY JOSEPH | 1629 | §103§112 | Non-Final OA | — | Pending | Dec 06, 2024 |
| 18770318 | PHENYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | KIFLE, BRUCK | 1624 | DP | Non-Final OA | — | Pending | Jul 11, 2024 |
| 18389888 | METHODS OF TREATING GASTROINTESTINAL STROMAL TUMORS | SZNAIDMAN, MARCOS L | 1628 | §103 | Non-Final OA | — | Pending | Dec 20, 2023 |
| 18464519 | METHODS OF TREATING GASTROINTESTINAL STROMAL TUMORS | VALENROD, YEVGENY | 1628 | §103 | Final Rejection | 24d overdue | Pending | Sep 11, 2023 |
| 17845275 | USE OF 1-[4-BROMO-5-[1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL]-2-FLUOROPHENYL]-3-PHENYLUREA AND ANALOGS FOR THE TREATMENT OF CANCERS ASSOCIATED WITH GENETIC ABNORMALITIES IN PLATELET DERIVED GROWTH FACTOR RECEPTOR ALPHA | RODRIGUEZ, RAYNA B | 1628 | §103§112 | Final Rejection | 12d | Pending | Jun 21, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialDeciphera Pharmaceuticals LLC has 8 pending office actions as of October 2026, spread across 6 art units and 8 examiners.
John D Pak has the most, with 1 of Deciphera Pharmaceuticals LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
